Research Article

Endocan Is an Independent Predictor of Heart Failure-Related Mortality and Hospitalizations in Patients with Chronic Stable Heart Failure

Table 2

Endocan levels in chronic HF patients in regard to patient’s comorbidities.

Comorbidity (%)Endocan levels (median (IQR))

CADYes57 (47)3.37 (2.39-4.76)0.976
No63 (53)3.38 (2.48-4.85)
PADYes22 (18)3.61 (2.32-4.97)0.218
No98 (82)3.38 (2.48-4.85)
DMYes48 (40)3.51 (2.55-4.50)0.776
No72 (60)3.25 (2.40-4.89)
AHYes84 (70)3.30 (2.34-4.75)0.292
No36 (30)3.66 (2.82-5.01)
HLPYes70 (58)3.25 (2.28-4.28)0.401
No50 (42)3.92 (2.58-5.31)
KIYes52 (43)3.55 (2.44-4.97)0.309
No68 (57)3.26 (2.39-4.47)

CAD: coronary artery disease; PAD: peripheral artery disease; DM: diabetes mellitus; AH: arterial hypertension; HLP: hyperlipidemia; KI: kidney insufficiency.